Wixela Inhub Powder
Product Images NDC 63629-4989

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Wixela Inhub (NDC 63629-4989). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Instructions For Use Figure A (Image 01)

An illustration of the Wixela Inhub inhaler device labeled to indicate key components: the Dosage area, Dose Counter display showing the number 50, and the Grip section. The device is triangular with a rounded top and includes text and branding on the front face.*

FDA Label Image

Fluticasone Propionate Structural Formula (Image 02)

Chemical structure of fluticasone propionate, an active ingredient in Wixela Inhub inhalation powder.*

FDA Label Image

Salmeterol Zinofoate Structural Formula (Image 03)

Chemical structure diagram showing two distinct molecular structures, representing the active ingredients fluticasone propionate and salmeterol in the product Wixela Inhub.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 04)

A line graph illustrating the percentage change in FEV1 over a 12-week period for four treatment groups: fluticasone propionate and salmeterol inhalation powder (100 mcg/50 mcg twice daily), fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The graph shows improvement trends in lung function measurements, with data points and sample sizes indicated at various weeks.*

FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 05)

A line graph titled 'First Treatment Day' depicting the percentage change in FEV1 over 12 hours post-dose for four groups: fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The vertical axis shows % change in FEV1 from baseline, and the horizontal axis shows time in hours.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 06)

A line graph titled 'Last Treatment Day (Week 12)' showing the percent change in FEV1 relative to Day 1 baseline over 12 hours. It compares four groups: fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo, with time on the x-axis and percent change on the y-axis.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Image 07)

A line graph showing the percentage change in FEV1 (forced expiratory volume in 1 second) over 24 weeks and at endpoint for three treatments: fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg, salmeterol 50 mcg, and placebo. The graph tracks treatment response weekly and includes baseline FEV1 values and sample sizes for each group at different study points.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Image 08)

A line chart depicting the percentage change in FEV1 over 24 weeks comparing three groups: fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg twice daily, fluticasone propionate 250 mcg twice daily, and placebo. The chart includes baseline FEV1 values for each group and sample sizes at multiple time points.*

FDA Label Image

Instructions For Use Figure B (Image 09)

An instructional illustration showing the Wixela Inhub inhaler device with labeled parts including the air vents, yellow lever, mouthpiece cover, mouthpiece, and a person inhaling through the device. The image highlights the inhaler’s components used for respiratory administration of fluticasone propionate and salmeterol powder.*

FDA Label Image

Instructions For Use Figure C (Image 10)

Instructional illustration showing a hand holding a Wixela Inhub inhaler with a thumb pressing down on the dosing lever. An inset close-up highlights the dosage counter displaying the number 50, indicating remaining doses. The image demonstrates proper actuation technique for respiratory powder inhalation.*

FDA Label Image

Instructions For Use Figure D (Image 11)

An instructional illustration labeled Figure D showing a hand holding the Wixela Inhub inhaler device. A close-up inset highlights the inhaler’s mouthpiece with a protective cover partially opened, demonstrating how to hold and prepare the device for inhalation delivery of the powder formulation.*

FDA Label Image

Instructions For Use Figures E And F (Image 12)

Instructional illustrations demonstrating the use of the Wixela Inhub inhalation device. Figure E shows a person exhaling away from the device, while Figure F shows the person inhaling the medication from the mouthpiece of the inhaler.*

FDA Label Image

Instructions For Use Figure G (Image 13)

An instructional illustration showing a person holding a Wixela Inhub inhaler device, with a close-up inset highlighting the dosage counter displaying the number 59. This figure demonstrates how to view the remaining doses on the inhaler.*

FDA Label Image

Instructions For Use Figure H (Image 14)

Illustration showing a person rinsing their mouth over a sink, with water flowing from the faucet and the person leaning forwards. The image is likely an instructional figure related to respiratory inhalation drug use.*

FDA Label Image

Instructions For Use Refill Image 01 (Image 15)

An instructional diagram showing the inhaler counter display on the Wixela Inhub device. The display indicates "60 doses left," helping users track remaining doses for the fluticasone propionate and salmeterol powder inhalation product.*

FDA Label Image

Instructions For Use Refill Image 02 (Image 16)

An illustration showing a close-up of a dose indicator on an inhaler displaying the number 9, accompanied by the text '9 doses left' and an arrow pointing to the right. This depicts the dose counting feature for the Wixela Inhub inhalation powder device.*

FDA Label Image

Instructions For Use Refill Image 03 (Image 17)

Wixela Inhub inhalation powder packaging label showing fluticasone propionate and salmeterol powder for respiratory inhalation. Visible indication of 0 doses left on the dose counter. The label also includes the Bryant Ranch Prepack logo and usage instructions partially visible on the left side.*

FDA Label Image

Label (Lbl636294989)

Wixela Inhub Inhalation Powder label showing fluticasone propionate 250 mcg and salmeterol 50 mcg per dose. The label states the inhalation device contains 60 doses of powder, for oral inhalation only, manufactured and relabeled by Bryant Ranch Prepack. Instructions include storage conditions, dose discard information, and usage directions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.